Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC)
| Autor: | Jane Bromund, H. Zeigler, W. G. Harker, J. T. Beck, S. J. Hager, J. E. Reeves, Denise A. Yardley, R. Borson, D. Drosick, W. L. Horvath, Datchen Fritz Tai |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy Taxane Bevacizumab business.industry medicine.medical_treatment HER2 negative Phases of clinical research medicine.disease Metastatic breast cancer Gemcitabine Surgery First line treatment Internal medicine medicine business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 29:1052-1052 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.1052 |
| Popis: | 1052 Background: Bevacizumab with chemotherapy has shown improvement in progression-free survival (PFS) in MBC patients (pts) (Miller 2007; Miles 2008; Brufsky 2009; Robert, et al 2009). We examine... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|